Drug intelligence / Profile preview

hydroxychloroquine + sofosbuvir + daclatasvir

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of hydroxychloroquine, sofosbuvir, and daclatasvir that was investigated for the treatment of moderate to severe COVID-19. Sofosbuvir is a nucleotide inhibitor of the viral RNA polymerase NS5B, daclatasvir is a viral NS5A inhibitor, and hydroxychloroquine was initially used as part of standard care for COVID-19 early in the pandemic. Clinical trials showed that adding sofosbuvir and daclatasvir to standard care (which included hydroxychloroquine) significantly reduced the duration of hospital stay compared to standard care alone.

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on hydroxychloroquine + sofosbuvir + daclatasvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxychloroquine + sofosbuvir + daclatasvir.

Explore the full profile